Webinar: Inflammatory Disease Modeling for Preclinical Studies
Our webinar “Inflammatory Disease Modeling for Preclinical Studies” will be live at 1:00 PM EST on February 15th, 2023.
In this webinar, we will:
- Provide a brief overview on molecular mechanisms driving disease progression.
- Discuss modeling inflammatory diseases in wild-type and humanized mice, including psoriasis, atopic dermatitis, delayed type hypersensitivity, inflammatory bowel disease and experimental autoimmune encephalomyelitis.
- Evaluate in vivo efficacy of therapeutic agents in preclinical inflammatory disease mouse models.
About the Speaker & Panelists
Rebecca Soto, Ph.D. Scientist II/Associate Manager Content Marketing, Biocytogen Boston
Dr. Rebecca Soto completed her PhD in Biological and Biomedical Sciences from Harvard University. Using various animal models, her thesis work primarily focused on epigenetic regulation of developmental hematopoiesis. At Biocytogen, Rebecca provides scientists with the information they need to further their research goals.
Jenna Frame, Ph.D. Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston
Dr. Jenna Frame has worked with mouse and zebrafish models in the hematology/oncology field for over 15 years at the University of Rochester and Harvard Medical School. At Biocytogen, Jenna helps provide researchers with the information they need to select quality animal models and other preclinical services to advance their scientific discoveries.
Zhaoxue (Luke) Yu, Ph.D. Deputy General Manager & Global Head of Preclinical Pharmacology, Biocytogen Boston
Dr. Zhaoxue (Luke) Yu has more than 15 years of research and technical leadership experience in drug discovery and development for immune/autoimmune diseases, oncology, neurological diseases, ocular diseases and metabolic diseases, working with various therapeutic modalities including antibodies, biologics, small molecules, mRNAs, and AAVs. Prior to Biocytogen, Dr. Yu served as a pharmacology technical leader at Gemini Pharmaceuticals, Achillion Pharmaceuticals, and Alexion Pharmaceuticals. Dr. Yu has been a major contributor to multiple drug development programs from preclinical to clinical stages, some of which have subsequently obtained approvals by the FDA. Dr. Yu received his Ph.D in Neurobiology and M.D. in China. He has held postdoctoral research positions at institutions including Emory University, Yale University, and Harvard Boston Children’s Hospital.
Margaret Barlow, Ph.D. Sr. Business Development Manager I, Biocytogen Boston